Climate-related risk is increasingly shaping how pharmaceutical products are developed, manufactured and delivered.
In our report, aligned with the Task Force on Climate-related Financial Disclosures (TCFD), we outline how Kindeva integrates climate risk assessment and opportunities into our governance, strategy and risk management processes.
The report reflects our approach to identifying, assessing, and managing climate-related risks and outlines how we intend to report greenhouse gas emissions and set targets over time.
Key takeaways from the report include:
- Moderate heat-related risks are driving investment in site resilience and business continuity planning
- Climate risk assessment now spans multiple time horizons, supporting more informed strategic and operational decisions
- Transition risks are emerging through regulation and carbon costs, accelerating focus on emissions tracking and reduction initiatives
- Demand for more sustainable treatments continues to grow, shaping how we support partners and develop solutions
- Next-generation propellants (NGPs) support a seamless transition from traditional propellants to more sustainable alternatives, while ensuring pressurized metered dose inhalers (pMDIs) maintain performance at commercial scale
Download the report to learn more about how Kindeva is addressing climate-related risk and opportunity →
Download FileRelated resources
Explore our other resources to discover valuable insights on the latest trends in drug delivery.
Parenteral capabilities overview
Next-generation biologics and combination products require precision and close coordination between drug delivery technologies and manufacturing execution. Kindeva advances parenteral programs across development and commercial supply by bringing together device expertise, aseptic manufacturing and scalable operations. Why choose Kindeva for your parental program Large-scale sterile fill finish The Bridgeton site supports vial, cartridge and prefilled […]
Learn MoreNavigating the green revolution: Why next-generation propellants are critical for pMDIs
The imperative to address climate change is reshaping industries worldwide, and pharmaceutical manufacturers are no exception. In respiratory medicine, the spotlight has fallen on pressurized metered-dose inhalers (pMDIs). While crucial for millions of patients, pMDIs harness propellants with a global warming potential (GWP) many times higher than CO2. This significant environmental footprint is a critical […]
Learn MoreWhere the propellants are greener: Inside the MDI facility of the future
As the pharmaceutical industry accelerates toward net-zero goals, inhalation therapies face unique scrutiny. Pressurized metered-dose inhalers (pMDIs) remain vital for millions of patients, yet their reliance on legacy propellants presents a sustainability challenge. To address this, Kindeva has established its UK headquarters and MDI Center of Excellence in Loughborough, a facility purpose-built to lead the […]
Learn More
Career journeys blog 4: Grace Guo
In this story, we meet Grace Guo, Manager of Client Portfolio Relationship Management, whose pathway at Kindeva has grown through clear communication, strategic thinking and a strong focus on people.
Learn More
The next leap in skin-based drug delivery: How dermal delivery platforms are transforming tomorrows for patients
Skin-based drug delivery is gaining attention as patients and healthcare systems look for treatments that support at-home administration and remove the need for needle-based injections. As this shift accelerates, developers are investing in technologies that improve usability without compromising performance. These platforms are opening new possibilities for therapies that rely on reliable, patient-preferred delivery. A […]
Learn More
Webinar | A Bridge to the Future of Aseptic Manufacturing: A Pharma 4.0 Case Study
Growing demand for high-quality sterile fill finish capacity is putting pressure on development timelines and supply programs across the industry. As expectations for Annex 1 alignment, agility and data-driven control rise, partners need facilities designed to keep pace with evolving requirements. In this on-demand webinar, Chad Hafer, Director of Technical Operations, Aseptic Fill Finish at […]
Learn More
Career journeys blog 3: Lauren Harrison
In this story, we meet Lauren Harrison, a formulation scientist who began her path as an apprentice and has spent the last decade building a career rooted in curiosity, hands-on learning and collaboration.
Learn More
Navigating the transition to next-generation propellants for pMDIs | On-demand webinar
Regulators, health systems and patients expect meaningful progress on sustainability. For pressurized metered dose inhalers (pMDIs), this means planning the transition to low global warming potential (low-GWP) next-generation propellants (NGPs) now, not at the end of the decade. In this webinar with Pharmaceutical Technology, Craig Somerville, Senior Vice President of Kindeva’s pMDI business unit, shares […]
Learn More
Beyond the contract: Driving transformational partnerships with manufacturing… and more
Achieving scientific breakthroughs is just one hurdle in today’s drug development and manufacturing process aimed at improving patient outcomes. Bringing a new therapy to market requires meticulous execution and clear communication at every step. Unfortunately, even the most groundbreaking scientific advancements can be delayed or even entirely abandoned due to poor performance from partners. This […]
Learn MoreLet’s transform tomorrow together
Every patient deserves a brighter tomorrow. As your strategic partner, we are dedicated to building your lasting legacy and helping you fast-track healthier tomorrows. You dream it, we deliver it.